Get started
Author

Helen Byomire Ndagije

Observed names: H. Byomire, H. Ndagije, H.B. Ndagije, Helen B Ndagije, Helen B. Ndagije, Helen Bomire Ndagije, Helen Byomire, Helen Byomire Ndagijje, Helen Ndagije, Hellen Byomire Ndagije, Ndagije HB, Ndagije, Helen, Ndagije, Helen Byomire
ORCID: 0000-0001-5802-4791
Observed ORCID: 0000-0001-5802-4791
OpenAlex ID: A5033916367
Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants
2014 · Ronald Kiguba, Charles Karamagi, et al. · BMJ Open · 41
PDF
Navigating duplication in pharmacovigilance databases: a scoping review
2024 · Ronald Kiguba, Gerald Isabirye, et al. · BMJ Open · 36
PDF
The Burden of Adverse Drug Reactions Due to Artemisinin-Based Antimalarial Treatment in Selected Ugandan Health Facilities: An Active Follow-Up Study
2018 · Helen Byomire Ndagije, Victoria Nambasa, et al. · Drug Safety · 29
PDF
Targeted Spontaneous Reporting of Suspected Renal Toxicity in Patients Undergoing Highly Active Anti-Retroviral Therapy in Two Public Health Facilities in Uganda
2015 · Helen Ndagije, Victoria Nambasa, et al. · Drug Safety · 23
PDF
Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda
2019 · Deogratius Ssemwanga, Juliet Asio, et al. · Journal of Antimicrobial Chemotherapy · 22
PDF
Medication Error Disclosure and Attitudes to Reporting by Healthcare Professionals in a Sub-Saharan African Setting: A Survey in Uganda
2015 · Ronald Kiguba, Paul Waako, et al. · Drugs - Real World Outcomes · 22
PDF
Drug safety in Africa: a review of systems and resources for pharmacovigilance
2023 · Helen Byomire Ndagije, David Walusimbi, et al. · Expert Opinion on Drug Safety · 21
Antimicrobial consumption surveillance in Uganda: Results from an analysis of national import data for the human health sector, 2018–2021
2023 · Marion Murungi, Helen Byomire Ndagije, et al. · Journal of Infection and Public Health · 20
Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study
2023 · Ronald Kiguba, Henry Zakumumpa, et al. · Drug Safety · 19
PDF
Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study
2021 · Henry Zakumumpa, Freddy Eric Kitutu, et al. · BMC Infectious Diseases · 18
PDF
Evaluation of the Clinical Use of Ceftriaxone among In-Patients in Selected Health Facilities in Uganda
2021 · Paul Kutyabami, Edson Ireeta Munanura, et al. · Antibiotics · 17
PDF
A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda
2010 · A. Kamali, H. Byomire, et al. · Sexually Transmitted Infections · 17
Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
2022 · Henry Zakumumpa, Ronald Kiguba, et al. · BMC Infectious Diseases · 16
PDF
Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline Concordance
2020 · Victoria Nambasa, Helen B. Ndagije, et al. · Antibiotics · 15
PDF
The effect of community dialogues and sensitization on patient reporting of adverse events in rural Uganda: Uncontrolled before-after study
2019 · Helen Byomire Ndagije, Leonard Manirakiza, et al. · PLoS ONE · 15
PDF
Adverse Drug Reaction Onsets in Uganda’s VigiBase®: Delayed International Visibility, Data Quality and Illustrative Signal Detection Analyses
2018 · Ronald Kiguba, Helen B. Ndagije, et al. · Pharmaceutical Medicine · 14
PDF
The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is Needed
2023 · Manal M. Younus, Mayada Alkhakany, et al. · Drug Safety · 13
PDF
Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial
2022 · Ronald Kiguba, Norah Mwebaza, et al. · BMJ Open · 12
PDF
Expanding regulatory science: Regulatory complementarity and reliance
2023 · Jackson K. Mukonzo, Helen Byomire Ndagije, et al. · Clinical and Translational Science · 11
PDF
Adverse drug reaction reporting with the Med Safety app in Uganda: a cluster-randomised, controlled trial
2025 · Ronald Kiguba, Helen B Ndagije, et al. · The Lancet Global Health · 6
National-Level Consumption of Antimicrobials in the Veterinary Sector in Uganda: A Report on Analysis of Import Data for 2021
2025 · Marion Murungi, Patrick Vudriko, et al. · Antibiotics · 6
PDF
The impact of the increase in import verification fees on local production capacity of selected medicines in Uganda
2023 · Kalidi Rajab, Solomon Onen, et al. · Journal of Pharmaceutical Policy and Practice · 6
PDF
Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting
2020 · Ronald Kiguba, Helen Byomire Ndagije, et al. · Malaria Journal · 6
PDF
Rare, Serious, and Comprehensively Described Suspected Adverse Drug Reactions Reported by Surveyed Healthcare Professionals in Uganda
2015 · Ronald Kiguba, Charles Karamagi, et al. · PLoS ONE · 6
PDF
Evaluating the Glycemic Effects of Dolutegravir and Its Predictors Among People With Human Immunodeficiency Virus in Uganda: A Prospective Cohort Study
2024 · Collins Ankunda, Curthbert Agolor, et al. · Open Forum Infectious Diseases · 5
PDF
Works count: 69
Citation count: 461
H-index: 15
I10-index: 19
Year
Topic
Type